Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Zapping the brain to sharpen focus: a new hope for adult ADHD?

NCT ID NCT07652788

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether a gentle, non-invasive brain stimulation technique called transcranial direct current stimulation (tDCS) can reduce inattention in adults with ADHD. Forty adults with ADHD will receive either real or fake tDCS for five days in a row. Researchers will measure changes in attention and processing speed using questionnaires and thinking tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS)
What this could lead to
If it works, this could offer a non-drug option to help adults with ADHD manage inattention symptoms.
What could go wrong
This is a small, early-stage trial with only 40 participants. The effect may be small or not last, and tDCS may cause mild scalp discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient aged 18 to 60 years inclusive * Patient diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD), combined or predominantly inattentive presentation, previously established by a healthcare professional * Patients must be registered in the active caseload of the Adult Neurodevelopmental Disorders Unit (STNDA) * Stable psychotropic medication regimen for at least four weeks prior to inclusion, in terms of both molecule and dosage, particularly for methylphenidate, or no current psychotropic treatment. Medication must remain unchanged throughout study participation, unless medically justified changes are required * Patient with a cognitive status deemed sufficient by the unit's referring psychiatrist to ensure appropriate completion of the scales and tests included in the protocol * Free, informed, and written consent Exclusion Criteria: •General condition impairment (severe fatigue or marked weakness, convalescence after an acute illness or surgery, or recent alcohol consumption) Psychiatric and neurological disorders * Diagnosis of Autism Spectrum Disorder (ASD) * Diagnosis of personality disorder (Cluster A, B, C, or other), according to DSM-5-TR * Diagnosis of schizophrenia spectrum disorder or other psychotic disorders according to DSM-5-TR * Diagnosis of bipolar disorder with manic episode or history of manic episodes according to DSM-5-TR * Confirmed neurological disorder * Epilepsy or history of epileptic seizures Medical comorbidities * Patient with known or suspected cardiac disease * Patient with severe pulmonary disease * Patient with cerebrovascular disease (e.g., stroke) Dermatological and surgical contraindications * Patient with scalp lesions, open wounds, or skin conditions (severe acne, herpes, burns, skin fissures) * Patient with severe dermatitis, oozing eczema, or fragile scalp * Patient with major surgical scars * Patient with recent craniotomy Implantable devices and materials • Patient with a pacemaker or intracranial electrodes, presence of intracranial metal, or skull defects (e.g., post-craniectomy or trepanation without reconstruction) Other criteria: * Simultaneous participation in another non-pharmacological intervention provided in the STNDA day hospital (e.g., psychoeducation, cognitive remediation, body expression therapy, emotional regulation training) * Patient with non-pathological ASRS screening scores (fewer than 4 of the first 6 items rated "Very often") * Insufficient proficiency in the French language * Patient under legal guardianship, curatorship, or judicial protection * Pregnant or breastfeeding patient (based on clinical interview)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention deficit hyperactivity disorder (ADHD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.